Common Contracts
12 similar Registration Rights Agreement contracts by X4 Pharmaceuticals, Inc, Skye Bioscience, Inc., Establishment Labs Holdings Inc., others
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 13th, 2024 • Skye Bioscience, Inc. • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 11, 2024, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors signatory hereto. Capitalized terms used herein have the respective meanings ascribed thereto in that certain Securities Purchase Agreement, by and among the Company and the Investors, dated as of March 11, 2024 (the “Purchase Agreement”) unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 29th, 2024 • Skye Bioscience, Inc. • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of January 29, 2024, by and among Skye Bioscience, Inc., a Nevada corporation (the “Company”), and the Investors signatory hereto. Capitalized terms used herein have the respective meanings ascribed thereto in that certain Securities Purchase Agreement, by and among the Company and the Investors, dated as of January 29, 2024 (the “Purchase Agreement”) unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 9th, 2024 • Establishment Labs Holdings Inc. • Orthopedic, prosthetic & surgical appliances & supplies • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2024 by and among Establishment Labs Holdings Inc., a company organized under the laws of the British Virgin Islands (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of January 9, 2024 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 22nd, 2023 • Krystal Biotech, Inc. • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of May 21, 2023, by and among Krystal Biotech Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of May 21, 2023 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 16th, 2023 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of May 15, 2023, by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of May 15 2023 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 1st, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of June 30, 2022 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of June 30, 2022 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 3rd, 2022 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 3, 2022 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of March 3, 2022 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 5th, 2021 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 5, 2021 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of November 5, 2021 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 5th, 2021 • Neogenomics Inc • Services-testing laboratories • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of May 4, 2021 by and among NeoGenomics, Inc., a Nevada corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of May 4, 2021 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 19th, 2021 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 18, 2021 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of March 18, 2021 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 7th, 2020 • Syros Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of December 4, 2020 by and among Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of December 4, 2020 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 20th, 2019 • Savara Inc • Pharmaceutical preparations • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of December 20, 2019 by and among Savara Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of December 20, 2019 (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
